AFT Pharmaceuticals is pleased to announce the launch of new HYLO®-FRESH and HYLO-FORTE® eye drops to the Australian market. These preservative-free and phosphate-free eye drops are delivered in a unique medical device that provides an ingenious new solution for the treatment of dry eye, severe and chronic cases of dry eye, or post-surgery. The patented COMOD® bottle is an air-less multi-dose application system that ensures the precise delivery of at least 300 sterile and preservative-free drops in each 10ml pack. HYLO®-FRESH utilises high quality sodium hyaluronate (0.1%) to provide effective and long-lasting lubrication for dry eyes of moderate to medium severity. HYLO-FORTE® is formulated with an elevated concentration of sodium hyaluronate (0.2%) producing a high viscosity product that provides more intensive lubrication of severe or chronic cases of dry eye, without vision impairment. It is also suitable for use following surgery. HYLO®-FRESH and HYLO-FORTE® eye drops both have a use-up period of six months after opening, and are compatible with all contact lenses
AFT Pharmaceuticals is pleased to announce the launch of the new VitA-POS® eye ointment to the Australian market. VitA-POS® is a smooth, preservative-free eye ointment containing Vitamin A that prevents evaporation from the ocular surface during the night. It improves the tear film and provides valuable protection of the ocular surface during sleep for all forms and severities of dry eye. VitA-POS® is both preservative-free and phosphate-free, and contains the equivalent of 250 IU of Vitamin A per gram. VitA-POS ® eye ointment also has a use-up period of six months after opening, and more than 300 applications are possible from a 5g pack.
AFT Pharmaceuticals SE Asia Sdn Bhd09-Jan-2012
The AFT Pharma group is delighted to expand its operations to SE Asia with the establishment of a regional office in Kuala Lumpur. Mr Giles Moss has assumed leadership for this enterprise. Giles, originally a Pharmacist has held a number of senior Pharma positions in mid sized Pharma including in Asia. "AFT is delighted to have someone with Giles experience and in depth knowledge of business in Asia involved. For AFT, it is a logical extension to expand close to home and this will build on earlier licensing deals in Asia dating back to 2008" said Dr Atkinson, AFT Pharma CEO.
ORPHAN Drug Company28-Dec-2011
AFT Pharmaceuticals has commenced an orphan drug company with operations in Auckland, New Zealand; Sydney, Australia and Kuala Lumpur, Malaysia to effectively cover ANZ and SE Asia. The key management team at AFT Orphan are Mr Giles Moss who is an experienced Asia Pharma Regional Executive in Asia based in Malaysia and Dr Hartley Atkinson, founder and CEO of AFT Pharma. "This initiative has arisen from recognizing that few orphan drugs reach patients in Asia Pacific (following a survey of top orphan drugs sold in the US and whether they were available to Asia Pacific patients). There is great societal need for orphan drugs - the formation of AFT Orphan hopes to improve access for US and EU orphan drugs by leveraging our experience in accessing multiple markets in the region" said Orphan Director Mr. Moss. "The key here seems to be that there are many companies in western markets that need a fully serviced Pharma Company that is capable of fulfilling all the required Pharmacovigilance and Regulatory functions as well as interaction with Key Opinion Leaders and patient groups. Furthermore this is exactly the sort of business project that we just love to do where as a company we are also helping patients who are clearly not always getting the medicines that they should" said AFT Pharma CEO, Dr Atkinson
AFT Growth Continues23-Jun-2011
AFT Pharmaceuticals group sales grew again for the twelth consecutive year and exceeded $35 million for the first time. Group CEO Dr Hartley Atkinson is looking forward to further growth including in targeted export markets. Especially pleasing has been growth in the key Australian market since setting up the new Sydney office and reorganising and increasing our sales organisation.
Australian Product Announcement23-Jun-2011
In Australia, AFT Pharmaceuticals is delighted to achieve further PBS listings, Phenoxymethylpenicillin-AFT (Penicillin V) Oral Liquid 125mg/5ml & 250mg/5ml strengths on the PBS from 01 June 2011. This restores the original penicillin oral liquid strengths to the PBS adding to choice available to Australian doctors and patients.
PBS Listing - Ferro-Tabs23-Jun-2011
AFT Pharmaceuticals is pleased to announce that from 01 September 2011 it's iron replacement product Ferro-Tabs will be PBS Listed. "This will make iron replacement therapy more readily available for groups in need such as indigenious peoples or the elderly and will assist in the implementation of the recommendations made by the National Iron Deficiency Anaemia expert groups" said Group CEO, Dr Hartley Atkinson.
Australian Product Announcement23-Nov-2010
In Australia, AFT Pharma is delighted to confirm two further recent PBS listings, Micolette Microenemas and Fluconazole 50mg and 100mg IV injections. This adds further to AFT's growing list of niche PBS listings.
NZ Product Announcement23-Nov-2010
In New Zealand, AFT Pharma is delighted to confirm agreement for listing of four products on the Pharmaceutical Schedule, Budenocort Powder for Inhalation, Aramed, Acetadote IV and Provive MCT-LCT. "These new listings will add to AFT's extensive list of products on the Pharmaceutical Schedule", said CEO and founder Dr Hartley Atkinson.
Australian Market Update03-May-2010
AFT Pharma has made further progress in the Australian market settling in to its new office in Lane Cove, Sydney. Operations are fully supported by an extensive team including newly employed, Office Administrator Ivana Yaco, and ten full time sales representatives covering every state in Australia. AFT has also invested heavily in state of the art printing and direct mailing operations to enable additional coverage of our growing customer base. Sales have responded well to the increased resources with current growth of 50% per annum in a competitive market.
AFT Pharmaceuticals has released Maxigesic®, a new analgesic tablet which for the first time in NZ combines Paracetamol and the anti-inflammatory Ibuprofen to provide superior pain relief to patients than either agent on its own. AFT will supply Maxigesic® in NZ and Australia and is looking for a partner to sell the drug overseas. The global pain relief market is worth $27 billion a year and group CEO Dr Hartley Atkinson sees massive potential for this product to take a good share of that.
AFT growth continues for 31 Mar08 Year04-May-2008
AFT Pharmaceuticals group sales grew to $22.4 million for the 31st March 2008 year. Sales for this next financial year are targeted to be between $28-30 million announced group CEO, Dr Hartley Atkinson Further sales growth is anticipated in key Australian and NZ markets.
AFT Licensing deal in SE Asia04-May-2008
AFT Pharmaceuticals has reached agreement with Hoe Pharmaceuticals in Malaysia to license 3 niche pharmaceuticals for the rapidly growing SE Asian market. The first launches will be in Q3 in Malaysia "AFT is very excited to take this next step in our expansion" said group CEO, Dr Hartley Atkinson.
AFT was listed (Pharma News) as having the top % growth in PBS scripts in the Australian market and #6 in absolute script growth "This is consistent with the rapid growth in sales that we are seeing since the introduction of a dedicated AFT sales force in Australia" said group CEO, Dr Hartley Atkinson.
AFT Group Sales Growth continues at +40%22-Sep-2007
Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.
AFT Pharmaceuticals has increased its Australian presence with its own dedicated sales team of representatives visiting doctors and pharmacists. Strong sales growth (+50% p.a.) continues in the Australian market fuelled by new product introductions and growth of existing products.
The New Zealand branch of AFT is to launch an unprecedented seven new products in November and December 2006. We believe that this demonstrates our ability to launch new products in the market through our strong sales and distribution network.
AFT Pharmaceuticals Grows at 45% per annum03-Nov-2006
AFT Pharmaceuticals is continuing to experience strong growth in both the Australian and NZ markets with group turnover in excess of $16 million. Future sales are budgetted in excess of $20 million driven by growth from existing products and new launches.
PBS Listing of FerroF Tablets and Cromolux01-Nov-2006
AFT Pharmaceuticals Pty Ltd has just successfully launched Ferro-F tablets (iron and folic acid) and Cromolux (sodium cromoglycate eye drops 2%) on the Pharmaceutical Benefit Scheme (PBS) in Australia on 1 August. Stock is available from all major wholesalers.
AFT Pharmaceuticals has now marketed Ellgy cracked Heel cream in the New Zealand market for over a year and has reached a clear 2 position in this competitive market (IMS data) with a combination of rep promotion, print and TV advertising.